Evaluation of the Telehealth Integrated Care Model in Patients With Hyperlipidemia and Other Cardiometabolic Disease
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Cardiometabolic Disease
- Sponsor
- Peking University Third Hospital
- Enrollment
- 1302
- Locations
- 1
- Primary Endpoint
- changes of compliance rate of target treatment for hyperlipidemia
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The objective of this study is to evaluate the telehealth integrated care model for its clinical efficacy, medical resource utilization, health economics measurement, and satisfaction survey indicators in hyperlipidemia patients and other cardiometabolic diseases. The result of the study will provide evidence for the value of integrated model in the treatment of patients with cardiometabolic syndrome.
Detailed Description
Efficacy evaluation is critical for understanding the practical application effect of telehealth integrated mode in the therapy of cardiometabolic disease patients. We can comprehend the influence of the combination of online and offline models on patients' clinical curative effect, medication compliance, medical cost, and satisfaction by analyzing the curative effect and finding a scientific basis for clinical practice and policy formation. As a result, the purpose of this study is to assess the curative effect of hyperlipidemia patients with other cardiometabolic disease using a telehealth integrated model, as well as to investigate the potential benefits and risks of this model in the management of cardiometabolic disease.
Investigators
Zeng Lin, Ph. D.
Deputy Director of Research Center of Clinical Epidemiology
Peking University Third Hospital
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 16 years, and ≤ 85 years;
- •Diagnosis as hyperlipidemia with at least one of the following disease: hypertension or type 2 diabetes mellitus;
- •Agreed to be enrolled in this study.
Exclusion Criteria
- •Undergone percutaneous coronary intervention within one year in our hospital;
- •Severe LV dysfunction, such as LV ejection fraction \< 35%, or congestive heart failure with New York Heart Association (NYHA) functional class IV or Killip class IV;
- •Structural heart disease, or severe arrhythmia;
- •Severe liver or kidney diseases, endocrinology diseases, hematologic diseases, rheumatic immune system diseases, and malignancy;
- •could not complete at least one-year-followup.
Outcomes
Primary Outcomes
changes of compliance rate of target treatment for hyperlipidemia
Time Frame: 12 month after recuitment
difference of compliance rate of target treatment for hyperlipidemia between endpoint with baseline
Secondary Outcomes
- changes of blood pressure(12 month after recuitment)
- changes of glycosylated hemoglobin(12 month after recuitment)
- changes of fasting glucose(12 month after recuitment)
- changes of LDL-c(12 month after recuitment)
- changes of triglyceride(12 month after recuitment)
- abnormal liver function(12 month after recuitment)
- abnormal kidney function(12 month after recuitment)
- Cardiovascular death(12 month)
- medication adherence rate(12 month)
- patients satisfaction(12 month)
- in person visit counts(12 month after recuitment)
- Rehospitalization(12 month)
- medical cost(12 month)
- telehealth visit counts(12 month after recuitment)